A Phase 3 interventional study of Golimumab and Methotrexate in Arthritis, Juvenile, sponsored by Janssen Research & Development, LLC. Completed at 38 sites in 9 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-11-14.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Arthritis, Juvenile by Johnson & Johnson — 1 open to participants now, 1 under way, 1 of them phase 3. Arthritis, Juvenile · Johnson & Johnson.
Among the 10 studies in Arthritis, Juvenile by Johnson & Johnson, this one is the only one that started in 2014, is one of 5 in phase 3, and was the 7th registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.
Browse Arthritis, Juvenile studies →1 of the 10 studies in Arthritis, Juvenile by Johnson & Johnson is open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, Argentina, Australia and 15 more countries
Ages 3+
By country, each count listing its studies:
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 130 is above the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 130 across the 9 interventional studies, 0 across the 1 observational. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Arthritis, Juvenile by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) of golimumab administered intravenously (IV) to pediatric participants with polyarticular (affects 5 or more joints) juvenile (an onset before age 16) idiopathic (of unknown cause) arthritis (joint pain) (pJIA) manifested by greater than or equal to (>=) 5 joints with active arthritis despite methotrexate (MTX) therapy for >= 2 months.
This is a single arm, Open-label (all people know the identity of the intervention), multi-center (when more than one hospital or medical school team work on a medical research study) study to determine the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time), efficacy (effectiveness) and safety of intravenous golimumab in participants with pJIA despite current treatment with methotrexate (MTX). The study will consist of 3 parts: Screening Phase (6 weeks); an Open-label Treatment Phase (consists of golimumab and MTX treatment for 52 weeks, wherein after Week 28, MTX dose change is allowed); Long-term Extension Phase (after Week 52 through Week 252) and Extended Treatment Period (after week 252). The maximal study duration for a participant will not exceed 832 weeks. All the eligible participants will be administered golimumab IV infusion and commercial MTX. Blood samples will be collected for evaluation of pharmacokinetics of study treatment. Participants' safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 80 milligram per meter square (mg/m\^2) as an intravenous (IV) infusion at Weeks 0, 4, and every 8 weeks thereafter up to Week 244, along with commercial methotrexate (MTX) weekly through Week 28 at the same Body Surface Area (BSA)-based dosage (10 to 30 mg/m\^2 per week for participants with BSA less than \[\<\] 1.67 meter square (m\^2), or minimum of 15 mg/week for participants with BSA greater than or equal to \[\>=\] 1.67 m\^2) as at the time of study entry. At Week 252, participants who meet the criteria for the optional Extended Treatment Period (ETP) may continue treatment with golimumab 80 mg/m\^2 every 8 weeks after completion of the Week 252 assessments.
Drug: Golimumab · Drug: Methotrexate
Golimumab 80 mg/m\^2 IV infusion at Weeks 0, 4, and every 8 weeks through Week 244. At Week 252, participants who meet the criteria for the optional Extended Treatment Period (ETP) may continue treatment with golimumab 80 mg/m\^2 every 8 weeks after completion of the Week 252 assessments.
Also known as: Simponi Aria
Methotrexate BSA-based dose (10 to 30 mg/m\^2 per week for participants with BSA \<1.67 m\^2, or minimum of 15 mg/week for participants with BSA \>=1.67 m\^2) weekly at least through Week 28.
Serum Trough Concentration (C-trough) of Golimumab
Serum golimumab trough concentration at Week 28 was reported.
Time frame: Week 28
Bayesian Area Under Curve at Steady State (AUCss) Over an 8-week Dosing Interval at Week 28
AUCss was defined as area under the plasma concentration-time curve at steady-state (based on steady-state assessment of trough concentrations or via modeling).
Time frame: Week 28
Serum Trough Concentration (C-trough) at Week 52
Serum golimumab trough concentration at Week 52 was reported.
Time frame: Week 52
Baysesian Area Under Curve at Steady State (AUCss) at Week 52
AUCss was defined as area under the plasma concentration-time curve at steady-state (based on steady-state assessment of trough concentrations or via modeling).
Time frame: Week 52
| Milestone | Golimumab |
|---|---|
| Started | 130 |
| Treated | 127 |
| Completed | 112 |
| Not completed | 18 |
| Withdrew: Adverse event | 11 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Other | 1 |
| Withdrew: Enrolled and not treated | 3 |
| Milestone | Golimumab |
|---|---|
| Started | 112 |
| Completed | 69 |
| Not completed | 43 |
| Withdrew: Other | 43 |
| Milestone | Golimumab |
|---|---|
| Started | 32 |
| Completed | 18 |
| Not completed | 14 |
| Withdrew: Adverse event | 1 |
| Withdrew: Physician decision | 3 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Other | 8 |
Serum golimumab trough concentration at Week 28 was reported.
| micrograms per milliliter (mcg/mL) | Golimumab |
|---|---|
| Serum Trough Concentration (C-trough) of Golimumab | 0.50 ± 0.427 |
AUCss was defined as area under the plasma concentration-time curve at steady-state (based on steady-state assessment of trough concentrations or via modeling).
| micrograms*day/milliliter (mcg*day/mL) | Golimumab |
|---|---|
| Bayesian Area Under Curve at Steady State (AUCss) Over an 8-week Dosing Interval at Week 28 | 399 (387 to 424) |
Serum golimumab trough concentration at Week 52 was reported.
| mcg/mL | Golimumab |
|---|---|
| Serum Trough Concentration (C-trough) at Week 52 | 0.52 ± 0.475 |
AUCss was defined as area under the plasma concentration-time curve at steady-state (based on steady-state assessment of trough concentrations or via modeling).
| mcg*day/mL | Golimumab |
|---|---|
| Baysesian Area Under Curve at Steady State (AUCss) at Week 52 | 421 (402 to 446) |
Collected over Treatment Period Arm: All cause mortality (From screening [-6 weeks] up to Week 52), Serious and Other AEs (Week 0 up to Week 52); LTE Period Arm: Week 52 up to Week 252; ETP Arm: Week 252 up to Week 420. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Period (Week 0 to 52): Golimumab 80 mg/m^2 IV q8w | 1/127 (0.8%) | 9/127 (7.1%) | 74/127 (58.3%) |
| LTE Period (Week 52 to 252): Golimumab 80 mg/m^2 IV q8w | 1/127 (0.8%) | 18/127 (14.2%) | 57/127 (44.9%) |
| ETP (Week 252 to 420): Golimumab 80 mg/m^2 IV q8w | 0/32 (0%) | 3/32 (9.4%) | 8/32 (25%) |
| Event | Treatment Period (Week 0 to 52): Golimumab 80 mg/m^2 IV q8w | LTE Period (Week 52 to 252): Golimumab 80 mg/m^2 IV q8w | ETP (Week 252 to 420): Golimumab 80 mg/m^2 IV q8w |
|---|---|---|---|
| CalcinosisGeneral disorders | 0/127 | 1/127 | 1/32 |
| Ocular Implant ExposureGeneral disorders | 0/127 | 0/127 | 1/32 |
| AppendicitisInfections and infestations | 0/127 | 0/127 | 1/32 |
| MyopericarditisCardiac disorders | 0/127 | 1/127 | 0/32 |
| Supraventricular TachycardiaCardiac disorders | 0/127 | 1/127 | 0/32 |
| GlaucomaEye disorders | 0/127 | 1/127 | 0/32 |
| Retinal DetachmentEye disorders | 0/127 | 1/127 | 0/32 |
| ConstipationGastrointestinal disorders | 0/127 | 1/127 | 0/32 |
| Crohn's DiseaseGastrointestinal disorders | 0/127 | 1/127 | 0/32 |
| GastritisGastrointestinal disorders | 0/127 | 1/127 | 0/32 |
| Event | Treatment Period (Week 0 to 52): Golimumab 80 mg/m^2 IV q8w | LTE Period (Week 52 to 252): Golimumab 80 mg/m^2 IV q8w | ETP (Week 252 to 420): Golimumab 80 mg/m^2 IV q8w |
|---|---|---|---|
| Upper Respiratory Tract InfectionInfections and infestations | 28/127 | 19/127 | 1/32 |
| NasopharyngitisInfections and infestations | 22/127 | 16/127 | 2/32 |
| Juvenile Idiopathic ArthritisMusculoskeletal and connective tissue disorders | 14/127 | 18/127 | 2/32 |
| HeadacheNervous system disorders | 14/127 | 6/127 | 1/32 |
| GastroenteritisInfections and infestations | 6/127 | 12/127 | 1/32 |
| Urinary Tract InfectionInfections and infestations | 1/127 | 12/127 | 0/32 |
| ArthritisNervous system disorders | 4/127 | 7/127 | 3/32 |
| NauseaGastrointestinal disorders | 11/127 | 7/127 | 0/32 |
| VomitingGastrointestinal disorders | 10/127 | 5/127 | 0/32 |
| Abdominal PainGastrointestinal disorders | 8/127 | 2/127 | 0/32 |
Full analysis set included all participants who received at least 1 dose of study agent.
| Age, Continuous(years) | Golimumab |
|---|---|
| Mean | 11.6 ± 3.85 |
| Sex: Female, Male(Participants) | Golimumab |
|---|---|
| Female | 93 |
| Male | 34 |
| Ethnicity (NIH/OMB)(Participants) | Golimumab |
|---|---|
| Hispanic or Latino | 63 |
| Not Hispanic or Latino | 62 |
| Unknown or Not Reported | 2 |
| Race/Ethnicity, Customized(Participants) | Golimumab |
|---|---|
| American Indian or Alaska Native | 4 |
| Asian | 1 |
| Black or African American | 5 |
| More than one race | 4 |
| Other | 28 |
| White | 85 |
| Region of Enrollment(Participants) | Golimumab |
|---|---|
| ARGENTINA | 18 |
| BRAZIL | 16 |
| CANADA | 7 |
| CHILE | 7 |
| ISRAEL | 2 |
| MEXICO | 25 |
| RUSSIAN FEDERATION | 14 |
| SOUTH AFRICA | 15 |
| UNITED STATES | 23 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2014 to primary completion in Jul 2018, 42 months.
Results were first posted in Nov 2020, 2 years 4 months after primary completion. A results delay was requested in Jul 2019.
Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 42 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Golimumab · Methotrexate
Janssen Research & Development, LLC →